NDC 0310-4700

LUMOXITI

Moxetumomab Pasudotox

LUMOXITI is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Astrazeneca Pharmaceuticals Lp. The primary component is Moxetumomab Pasudotox.

• Product ID: 0310-4700_3c0aedca-0378-43ce-adcf-0b1caf0da3be
• NDC: 0310-4700
• Product Type: Human Prescription Drug
• Proprietary Name: LUMOXITI
• Generic Name: Moxetumomab Pasudotox
• Dosage Form: Injection, Powder, Lyophilized, For Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2018-10-24
• Marketing Category: BLA / BLA
• Application Number: BLA761104
• Labeler Name: AstraZeneca Pharmaceuticals LP
• Substance Name: MOXETUMOMAB PASUDOTOX
• Active Ingredient Strength: 1 mg/mL
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 0310-4700-01

1 VIAL in 1 CARTON (0310-4700-01) > 1 mL in 1 VIAL

• Marketing Start Date: 2018-10-24
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0310-4700-01 [00310470001]

LUMOXITI INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

• Marketing Category: BLA
• Application Number: BLA761104
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2018-10-24

Drug Details

Active Ingredients

Ingredient	Strength
MOXETUMOMAB PASUDOTOX	1 mg/mL

OpenFDA Data

• SPL SET ID: d6510282-1a57-4614-9859-299a227a089c
• Manufacturer:
  • AstraZeneca Pharmaceuticals LP
• UNII:
  • 2NDX4B6N8F
  • 6OZP39ZG8H
• RxNorm Concept Unique ID - RxCUI:
  • 2099314
  • 2099309

NDC Crossover Matching brand name "LUMOXITI" or generic name "Moxetumomab Pasudotox"

NDC	Brand Name	Generic Name
0310-4700	LUMOXITI	moxetumomab pasudotox
73380-4700	LUMOXITI	MOXETUMOMAB PASUDOTOX